Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...